Department of Medicine, St Luke's University Health Network-Easton Campus, 250 S, 21st Street, Easton, PA, 18042, USA.
Sci Rep. 2022 Apr 1;12(1):5553. doi: 10.1038/s41598-022-09639-2.
Coronavirus disease 2019 (COVID-19) is a new pandemic the entire world is facing since December of 2019. Several risk factors are identified in developing severe disease and one of which is preexisting type 2 diabetes mellitus. Metformin is known to have host-directed anti-viral and anti-inflammatory properties. However, whether these effects offer lower mortality remains unclear. In this retrospective study, we aim to address whether metformin use prior to admission decreases mortality in patients with COVID-19 and pre-existing type 2 diabetes mellitus. A total of 1356 hospitalized patients with COVID-19 and pre-existing type 2 diabetes mellitus was analyzed by multivariable regression. Covariates that potentially confound the association were further adjusted using propensity score matching or inverse probability of treatment weighting. We found that metformin therapy prior to admission in patients with COVID-19 and type 2 diabetes mellitus was significantly associated with less primary outcome events including in-hospital mortality and hospice care enrollment with an odds ratio (OR) of 0.25 (95% CI 0.06-0.74) and less in-hospital length of stay, compared to the non-metformin group. Our results provide supporting evidence that metformin may confer increased survival in patients with COVID-19 and type 2 diabetes mellitus treated with metformin prior to hospitalization.
2019 年冠状病毒病（COVID-19）是自 2019 年 12 月以来全球面临的一种新的大流行病。在发生严重疾病的过程中有几个危险因素，其中之一是预先存在的 2 型糖尿病。二甲双胍具有宿主导向的抗病毒和抗炎特性已为人所知。然而，这些效果是否能降低死亡率尚不清楚。在这项回顾性研究中，我们旨在探讨 COVID-19 和预先存在的 2 型糖尿病患者入院前使用二甲双胍是否降低死亡率。通过多变量回归分析了总共 1356 名患有 COVID-19 和预先存在的 2 型糖尿病的住院患者。使用倾向评分匹配或治疗反概率加权进一步调整了可能混淆关联的协变量。我们发现，COVID-19 和 2 型糖尿病患者入院前使用二甲双胍治疗与主要结局事件（包括住院死亡率和临终关怀入院）的发生率显著降低相关，比值比（OR）为 0.25（95%CI 0.06-0.74），住院时间也较短，与非二甲双胍组相比。我们的研究结果提供了支持性证据，表明在 COVID-19 和 2 型糖尿病患者中，入院前使用二甲双胍治疗可能会增加患者的生存率。
